David Esposito

David is President and Chief Executive Officer of ONL Therapeutics.

He is an experienced healthcare executive who has built and scaled multiple companies that have resulted in successful exits. David is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. Armune BioScience was sold to Exact Sciences in 2017. He was also President of Phadia US Inc. and he played a pivotal role in the sale of the business to Thermo Fisher Scientific in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing, and commercial strategy for the US Division.

David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his BS degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.